Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells

Catharina Wenk, MD, Anne-Kathrin Garz, MSc, Christina Huberle, MD, Sonja Grath, PhD, Denis Witham, Marie Weickert, Msc, Julia Niggemeyer, Msc, Judith Hecker, MD, Michele Kyncl, MSc, Catharina Müller-Thomas, MD, Christopher Mulholland, MSc, Robert A.J. Oostendorp, PhD, Klaus H. Metzeler, MD, Christian Peschel, MD, Katharina S Götze, MD

Blood (2017) 130 (Supplement 1): 1683.

https://doi.org/10.1182/blood.V130.Suppl_1.1683.1683

Published: 2017

Journal Articles

Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure

Stefanie Jilg, MD, Johanna Kauschinger, MDcal student, Veronika Reidel, MDcal student, Catharina Müller-Thomas, MD, Richard Hauch, MDcal student, Johannes Schauwecker, MD, Burkhard Schmidt, MD, Ulrike Höckendorf, Dipl. Humanbiol., Christian Peschel, MD, Katharina Götze, MD, Philipp J. Jost, MD

Blood (2016) 128 (22): 4297.

https://doi.org/10.1182/blood.V128.22.4297.4297

Published: 2016

Journal Articles

Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML)

Peter Herhaus, Stefan Habringer, Kathrin Philipp-Abbrederis, Tibor Vag, Carlos Gerngroß, Alexander Höllein, Torben Altmann, Catharina Müller-Thomas, Julia Slotta-Huspenina, Christian Peschel, Markus Schwaiger, Hans-Jürgen Wester, Mareike Verbeek, Karsten Spiekermann, Katharina Götze, Ulrich Keller

Blood (2015) 126 (23): 1275.

https://doi.org/10.1182/blood.V126.23.1275.1275

Published: 2015

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Catharina Müller-Thomas, MD, Martina Rudelius, MD, Ina Rondak, PhD, Torsten Haferlach, MD, Julie Schanz, MD, Burkhard Schmidt, MD, Markus Kremer, MD, Ulrich Germing, MD, Uwe Platzbecker, MD, PhD, Christian Peschel, Katharina Götze, MD

Blood (2013) 122 (21): 2797.

https://doi.org/10.1182/blood.V122.21.2797.2797

Published: 2013

Journal Articles

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Andrea Kuendgen, MD, Catharina Müller-Thomas, MD, Petra Urbaniak, Michael Lauseker, Torsten Haferlach, MD, Tamara Alpermann, Andreia Albuquerque, PhD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Barbara Hildebrandt, PhD, Brigitte Royer-Pokora, PhD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Katharina Götze, MD

Blood (2013) 122 (21): 2757.

https://doi.org/10.1182/blood.V122.21.2757.2757

Published: 2013

Journal Articles

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

Andrea Kuendgen, MD, Jenny Seidler, Michael Lauseker, Torsten Haferlach, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Barbara Hildebrandt, PhD, Catharina Müller-Thomas, MD, Beate Betz, PhD, Rainer Haas, MD, Norbert Gattermann, MD, Brigitte Royer-Pokora, PhD, Katharina Götze, M.D., Ulrich Germing, MD

Blood (2013) 122 (21): 2758.

https://doi.org/10.1182/blood.V122.21.2758.2758

Published: 2013

NARROW

Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells

Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure

Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML)

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only